CHMP Backs Six-Weekly Cemiplimab Dosing Across EU Indications
The CHMP has issued a positive opinion backing six-weekly cemiplimab dosing across all EU indications, potentially halving annual infusion visits.
Topic
Pd 1
Topic
Topic
Topic
The CHMP has issued a positive opinion backing six-weekly cemiplimab dosing across all EU indications, potentially halving annual infusion visits.